

Maurizio Severino, MD-PhD



University Hospital Bonn, DZNE (Deutsches Zentrum für neurodegenerative Erkrankungen)

Position (Postdoctoral researcher)

E-Mail: (maurizio.severino@dzne.de)

Research Expertise

I am a MD, PhD and board certified neurologist from Italy, with several years of experience in general neurology, neurology intensive care and stroke unit, and about 5 years of experience in basic neuroscience. During my PhD, partly funded from Lundbeck (DK), I worked on Alzheimer's dementia, earning experience in transgenic mice expressing human A β amyloid, and microglia driven neuroinflammatory response, A β pathology and behavior. Both at clinical and basic science level I am particularly interested in neurodegenerative disorders. I am member of national and international medical and scientific associations as well as board certified neurologist in several EU countries.

Education / Training

1995–2001: MD at “Federico II” University, Medicine-Surgery Faculty (IT)

2001–2006: Residency in Neurology - “Federico II” University (IT)

2009–2015: PhD in neuroscience - University of Southern Denmark (DK)

Appointments / Positions Held

2001–2006: Residency in Neurology – Federico II University (IT)

2005–2006: Research Fellow in neuroscience at Copenhagen University (DK)

2006: Visitor scientist Danish Research Centre for Magnetic Resonance (DK)

2007: Research fellow at Lund University (SE) – 6 months

2008: Senior specialist consultant in Neurology (NO)

2009–2012: PhD student at University of Southern Denmark (DK)

2009–2012: Locum Specialist consultant in neurology (NO, SE)

2012: Research Assistant at University of Southern Denmark (DK)

2012–2019: Senior Specialist in neurology (Oslo, NO)

2013–2019: Private Senior consultant neurologist (Oslo, NO)

Honors / Awards

2009: Lundbeck Fund

2009: Danish fund for progress in Medical Research

2011: Lundbeck Fund

Most Relevant Publications

1. **Severino M**, Pedersen AF, Trajkovska V, Christensen E, Lohals R, Veng LM, Knudsen GM, Aznar S. Selective immunolesion of cholinergic neurons leads to long-term changes in 5-HT_{2A} receptor levels in hippocampus and frontal cortex. *Neurosci Lett.*, 2007.

2. Olesen LØ, Bouzinova EV, **Severino M**, Sivasaravanaparan M, Hasselstrøm JB, Finsen B, Wiborg O. Behavioural Phenotyping of APP_{swe}/PS1_{ΔE9} Mice: Age-Related Changes and Effect of Long-Term Paroxetine Treatment. *PLoS One*, 2016.

3. Olesen LØ, Sivasaravanaparan M, **Severino M**, Bouzinova E, Babcock A, West M, Wiborg O, Finsen B. Neuron number and neurogenesis in the dentate gyrus of aged APP_{swe}/PS1_{ΔE9} transgenic mice: Effect of long-term treatment with paroxetine. *Neurobiology of Disease*, 2017.

4. Von Linstow CU, **Severino M**, Metaxas A, Waider J, Lesch KP, Gramsbergen JB, Finsen B. Effect of ageing and AD-like pathology on brain monoamines in mice. *Journal of Neurochemistry*, 2017

5. Olesen LØ, Sivasaravanaparan M, Severino M, Babcock AA, Bouzinova EV, West MJ, Wiborg O, Finsen B. Neuron and neuroblast numbers and cytotogenesis in the dentate gyrus of aged APP_{swe}/PS1_{ΔE9} transgenic mice: Effect of long-term treatment with paroxetine. *Neurobiol Disease*, 2017

6. **Severino M**, Sivasaravanaparan M, Olesen ØL, von Linstow CU, Bouzinova EV, Metaxas A, Babcock AM, Manzoor AK, Lambertsen KL, Hasselstrøm J, Gramsbergen JB, Wiborg O, Finsen B. Modulation of serotonin signaling has no effect on established amyloid pathology in the APP_{swe}PS1_{ΔE9} mouse model of Alzheimer's disease. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, 2018

7. Olesen LØ, Sivasaravanaparan M, Severino M, Babcock AA, Bouzinova EV, West MJ, Wiborg O, Finsen B. Corrigendum to "Neuron and neuroblast numbers and cytotogenesis in the dentate gyrus of aged APP_{swe}/PS1_{ΔE9} transgenic mice: Effect of long-term treatment with paroxetine" [*Neurobiol Dis.* 2017; 104: 50-60]. *Neurobiol Dis.* 2019 Apr;124:573. doi: